A carregar...

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

Sipuleucel-T was approved by the US Food and Drug Administration on April 29, 2010, as an immunotherapy for late-stage prostate cancer. To manufacture sipuleucel-T, mononuclear cells harvested from the patient are incubated with a recombinant prostatic acid phosphatase (PAP) antigen and reinfused. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huber, Marie L., Haynes, Laura, Parker, Chris, Iversen, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3283534/
https://ncbi.nlm.nih.gov/pubmed/22232132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djr514
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!